🍽️ flecainide acetate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of flecainide acetate,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by flecainide acetate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Ruminococcus genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Agathobacter rectalis species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of flecainide acetate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0 0
ADHD 0.8 0.3 1.67
Allergic Rhinitis (Hay Fever) 0.1 0.2 -1
Allergies 0.7 0.9 -0.29
Allergy to milk products 0.6 0.1 5
Alzheimer's disease 0.7 1 -0.43
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.4 0.5 -0.25
Ankylosing spondylitis 0.2 0.6 -2
Anorexia Nervosa 0.6 -0.6
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 0.6 0 0
Atherosclerosis 0.5 0.5
Atrial fibrillation 0.7 0.1 6
Autism 1.4 1.4 0
benign prostatic hyperplasia 0.1 0.1
Bipolar Disorder 0.5 0.7 -0.4
Brain Trauma 0 0 0
Carcinoma 0.8 0.5 0.6
Celiac Disease 0.2 0.8 -3
Cerebral Palsy 0 0.5 0
Chronic Fatigue Syndrome 1.9 0.2 8.5
Chronic Kidney Disease 0.5 0.2 1.5
Chronic Lyme 0 0
Chronic Obstructive Pulmonary Disease (COPD) 0.1 -0.1
Chronic Urticaria (Hives) 0.2 0.1 1
Coagulation / Micro clot triggering bacteria 0.2 0.4 -1
Colorectal Cancer 0.8 0.1 7
Constipation 0.3 0.3
Coronary artery disease 0.5 0.5
COVID-19 1.8 2.2 -0.22
Crohn's Disease 1.1 1 0.1
cystic fibrosis 0.2 0.1 1
deep vein thrombosis 0.2 0.4 -1
Depression 2.4 1.6 0.5
Dermatomyositis 0 0
Eczema 0.1 0.1 0
Endometriosis 0.3 0.5 -0.67
Epilepsy 0.2 0.1 1
Fibromyalgia 0.1 -0.1
Functional constipation / chronic idiopathic constipation 1.3 0.3 3.33
gallstone disease (gsd) 0.5 0 0
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 0.2
Generalized anxiety disorder 0.2 0.3 -0.5
Graves' disease 0.1 0.1
Halitosis 0 0
Hashimoto's thyroiditis 0.2 0.1 1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.5 0.1 4
hyperglycemia 0.1 0.1 0
Hyperlipidemia (High Blood Fats) 0 0
hypertension (High Blood Pressure 0.6 0.3 1
Hypothyroidism 0.3 -0.3
Hypoxia 0 0
IgA nephropathy (IgAN) 0.4 -0.4
Inflammatory Bowel Disease 0.6 1.9 -2.17
Insomnia 0 0.1 0
Intracranial aneurysms 0.5 0.5
Irritable Bowel Syndrome 0.7 0.4 0.75
Liver Cirrhosis 0.6 0.5 0.2
Long COVID 0.7 1.9 -1.71
Low bone mineral density 0.1 -0.1
Lung Cancer 0.1 0.4 -3
ME/CFS with IBS 0.1 -0.1
ME/CFS without IBS 0.9 0.1 8
Menopause 0.3 0.3
Metabolic Syndrome 1.1 1 0.1
Mood Disorders 2.8 1.9 0.47
Multiple Sclerosis 1.5 0.9 0.67
Multiple system atrophy (MSA) 0.5 -0.5
Neuropathy (all types) 0.1 -0.1
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 0.9 -8
NonCeliac Gluten Sensitivity 0 0
Obesity 0.7 1.2 -0.71
obsessive-compulsive disorder 1.5 0.3 4
Osteoarthritis 0.1 0.4 -3
Osteoporosis 0.8 0 0
Parkinson's Disease 0.4 0.7 -0.75
Polycystic ovary syndrome 0.6 0.9 -0.5
Postural orthostatic tachycardia syndrome 0 0
Premenstrual dysphoric disorder 0 0
Psoriasis 0.7 0 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.9 0.2 3.5
Rosacea 0.6 0.6
Schizophrenia 1.1 0.5 1.2
scoliosis 0.6 -0.6
Sjögren syndrome 0.1 0.2 -1
Sleep Apnea 0.5 0.3 0.67
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.2 -1
Stress / posttraumatic stress disorder 0.2 0.6 -2
Systemic Lupus Erythematosus 0.5 0.6 -0.2
Tic Disorder 0.5 0 0
Tourette syndrome 0 0
Type 1 Diabetes 0.8 0.2 3
Type 2 Diabetes 1.1 0.9 0.22
Ulcerative colitis 0.6 0.3 1
Unhealthy Ageing 0.7 0.1 6

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.


The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)